- Home
- GHM vs GOSS Comparison
GHM vs GOSS Comparison
Compare GHM & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHM
- GOSS
- Stock Information
- Founded
- GHM 1936
- GOSS 2015
- Country
- GHM United States
- GOSS United States
- Employees
- GHM N/A
- GOSS N/A
- Industry
- GHM Industrial Machinery/Components
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- GHM Industrials
- GOSS Health Care
- Exchange
- GHM Nasdaq
- GOSS Nasdaq
- Market Cap
- GHM 577.9M
- GOSS 586.6M
- IPO Year
- GHM N/A
- GOSS 2019
- Fundamental
- Price
- GHM $52.24
- GOSS $3.20
- Analyst Decision
- GHM Strong Buy
- GOSS Strong Buy
- Analyst Count
- GHM 2
- GOSS 6
- Target Price
- GHM $60.00
- GOSS $8.60
- AVG Volume (30 Days)
- GHM 80.0K
- GOSS 4.4M
- Earning Date
- GHM 11-07-2025
- GOSS 11-06-2025
- Dividend Yield
- GHM N/A
- GOSS N/A
- EPS Growth
- GHM 184.08
- GOSS N/A
- EPS
- GHM 1.26
- GOSS N/A
- Revenue
- GHM $215,432,000.00
- GOSS $40,237,000.00
- Revenue This Year
- GHM $10.98
- GOSS N/A
- Revenue Next Year
- GHM $10.59
- GOSS $30.65
- P/E Ratio
- GHM $41.72
- GOSS N/A
- Revenue Growth
- GHM 14.64
- GOSS N/A
- 52 Week Low
- GHM $24.78
- GOSS $0.66
- 52 Week High
- GHM $58.00
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- GHM 59.38
- GOSS 55.45
- Support Level
- GHM $46.58
- GOSS N/A
- Resistance Level
- GHM $49.70
- GOSS $3.60
- Average True Range (ATR)
- GHM 1.91
- GOSS 0.25
- MACD
- GHM 0.43
- GOSS -0.06
- Stochastic Oscillator
- GHM 76.80
- GOSS 88.89
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.